BRUKINSA, a next-generation BTK inhibitor, is a recommended treatment option by NICE and its use is accepted by SMC and HSE for adult patients with CLL in treatment-naïve and relapsed/refractory (R/R) settings — a decision that is supported by robust data from multiple clinical studies[1–7]. CLL is a growing global concern[8–11] Incidence, morbidity and mortality […]
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: